This site is intended for US healthcare professionals only

Optune Lua^® is
NOW FDA-APPROVED for mNSCLC

together with a PD-1/PD-L1 inhibitor or docetaxel for adult patients who have progressed on or after a platinum-based regimen¹

Read the press release

mNSCLC, metastatic non–small cell lung cancer; PD-1/PD-L1, programmed cell death 1 protein/programmed cell death 1 ligand 1.

Register for Updates

*Required fields

First name^*

Last name^*

Email address^*

Confirm email address

ZIP Code^*

I am a^*

PatientHCPCaregiverOther

By clicking here, I am agreeing to the statements below and confirm that I have read and accept Novocure's Privacy Policy. I also affirm that I am at least eighteen (18) years of age or older. I authorize Novocure Inc. (Novocure), its affiliates, and companies working with Novocure to contact me by direct mail, email, telephone, and electronic message (including autodialed and pre-recorded calls and messages) for marketing purposes, such as: to keep me informed about products and patient support services; to provide me special offers regarding Novocure products and programs; to conduct market research or surveys; or other opportunities that may be of interest to me. I further understand that the information that I share with Novocure may be used by Novocure, its affiliates, and companies working with Novocure to develop future products, services, and programs. I understand that I may choose to no longer receive further communications from Novocure by following the unsubscribe instructions on the communication.^*

Reserve email*

Contact Us

Get 24/7 personalized support

MyNovocure^® can provide 24/7 assistance for your practice and patients throughout the treatment journey.

For patient assistance, insurance questions, technical support, physician information, and general inquiries, please contact MyNovocure support through either method below.

Call us any time of day:

(toll-free)

Or email us:

support@mynovocure.com

Reference: 1. Optune Lua for Non-Small Cell Lung Cancer (NSCLC). Physician Instructions for Use. Novocure; 2024.

Important Safety Information and Indication for Use

Contraindications

Do not use Optune Lua^® in patients with an electrical implant. Use of Optune Lua together with electrical implants has not been tested and may lead to malfunctioning of the implanted device.

Do not use Optune Lua in patients known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune Lua may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions, such as a fall in blood pressure and breathing difficulty.

Warnings and Precautions

Optune Lua can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure^® (the device manufacturer).

Do not prescribe Optune Lua for patients who are pregnant, whom you think might be pregnant, or who are trying to get pregnant, as the safety and effectiveness of Optune Lua in these populations have not been established.

The most common (≥10%) adverse events involving Optune Lua concurrent with PD-1/PD-L1 inhibitors or docetaxel were dermatitis, musculoskeletal pain, fatigue, anemia, dyspnea, nausea, cough, diarrhea, anorexia, pruritus, leukopenia, pneumonia, respiratory tract infection, localized edema, rash, pain, constipation, skin ulcers, and hypokalemia.

Other potential adverse effects associated with the use of Optune Lua include treatment related skin toxicity, allergic reaction to the adhesive or to the gel, overheating of the array leading to pain and/or local skin burns, infections at the site where the arrays make contact with the skin, local warmth and tingling sensation beneath the arrays, medical device site reaction, muscle twitching, and skin breakdown or skin ulcer.

If the patient has an underlying serious skin condition on the chest, evaluate whether this may prevent or temporarily interfere with Optune Lua treatment.

Indication For Use

Optune Lua is intended as a treatment concurrent with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non-small cell lung cancer who have progressed on or after a platinum-based regimen.

Please see full Instructions For Use (IFU) and Patient Information and Operation Manual (PIOM) for Optune Lua®.

Important Safety Information and Indication for Use

Contraindications

Do not use Optune Lua^® in patients with an electrical implant. Use of Optune Lua together with electrical implants has not been tested and may lead to malfunctioning of the implanted device.

Do not use Optune Lua in patients known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune Lua may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions, such as a fall in blood pressure and breathing difficulty.

Warnings and Precautions

Optune Lua can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure^® (the device manufacturer).

Do not prescribe Optune Lua for patients who are pregnant, whom you think might be pregnant, or who are trying to get pregnant, as the safety and effectiveness of Optune Lua in these populations have not been established.

The most common (≥10%) adverse events involving Optune Lua concurrent with PD-1/PD-L1 inhibitors or docetaxel were dermatitis, musculoskeletal pain, fatigue, anemia, dyspnea, nausea, cough, diarrhea, anorexia, pruritus, leukopenia, pneumonia, respiratory tract infection, localized edema, rash, pain, constipation, skin ulcers, and hypokalemia.

Other potential adverse effects associated with the use of Optune Lua include treatment related skin toxicity, allergic reaction to the adhesive or to the gel, overheating of the array leading to pain and/or local skin burns, infections at the site where the arrays make contact with the skin, local warmth and tingling sensation beneath the arrays, medical device site reaction, muscle twitching, and skin breakdown or skin ulcer.

If the patient has an underlying serious skin condition on the chest, evaluate whether this may prevent or temporarily interfere with Optune Lua treatment.

Indication For Use

Optune Lua is intended as a treatment concurrent with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non-small cell lung cancer who have progressed on or after a platinum-based regimen.

Please see full Instructions For Use (IFU) and Patient Information and Operation Manual (PIOM) for Optune Lua®.